BioPharmSignal logoBioPharmSignal

Biotech News

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Caribou (CRBU)CaribouConference / presentation

BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the

Related news

CRBUCaribou2026-11-04 14:00 EST

Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting

COGTCogent Biosciences2026-10-27 20:01 EST

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

EDITEditas Medicine2026-10-14 13:00 EST

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

CRBUCaribou2026-11-05 21:05 EST

Caribou Biosciences Reports Third Quarter 2026 Financial Results

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

View all latest news

Caribou

Allogeneic Cell Therapy Caribou Biosciences develops off-the-shelf CAR-T cell therapies using its CRISPR genome-editing platform. Its candidates incorporate multiple edits intended to improve persistence, antitumor activity and compatibility with donor-derived cells. Vispa-cel Vispacabtagene regedleucel, or vispa-cel, is an allogeneic...

Recent company news

CRBUCaribou2026-11-05 21:05 EST

Caribou Biosciences Reports Third Quarter 2026 Financial Results

CRBUCaribou2026-11-04 14:00 EST

Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting

CRBUCaribou2026-10-06 20:05 EST

Caribou Biosciences to Evaluate Strategic Alternatives

CRBUCaribou2026-08-13 20:05 EST

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

CRBUCaribou2026-06-29 12:00 EST

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Stock data

Close
0.41 USD
Market cap
230.1M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States